Towards a more effective healthcare regulation system in China China Health System Study Group Harvard School of Public Health Presented by Wensheng Fan,

Slides:



Advertisements
Similar presentations
JFDA & HAI Workshop Towards equitable and affordable medicine prices policy in Jordan 4-5 December 2007 Strategies to aid market entry and competition.
Advertisements

Devon Local Pharmaceutical Committees COMMUNITY PHARMACY POLICY AND DEVELOPMENTS Sue Taylor, Devon LPCs January 2004.
Medication Management
PRIVATE SECTORS PERSPECTIVE ON THE IMPLEMENTATION OF RULES AND REGULATIONS Dr. Chea Sam An General Manager Visalsok Poly Clinic Intercontinental Hotel.
IMPLEMENTATION OF HOSPITAL AUTONOMY: VIETNAM EXPERIENCES Health Strategy and Policy Institute - Vietnam.
World Health Organization
1 Binational Health Insurance Models APHA 2008 Annual Meeting William H. Dow Henry J. Kaiser Associate Professor of Health Economics UC-Berkeley.
November 26, Fall Forum Alberta’s Pharmaceutical Strategy and Programs Policy Recommendations.
Understanding the Role of Corporate Governance: Lessons from the ROSC Program Alex Berg February 2013.
Rational Use of Injections within National Drug Policies World health organisation Essential Drugs and Medicines Policy Safe Injection Global Network Cairo.
ECON 850 Health Economics Gilleskie Lecture 1: Introduction What is economics? What is health economics?
Copyright 2012 Delmar, a part of Cengage Learning. All Rights Reserved. Chapter 15 Globalization and Health: The World is Flattening.
Belize, May31,2006 Health Systems Strengthening Seminar Monitoring Health Systems Change/Health Reforms Service provision Dr J. Gernay.
Major Health Issues The Affordable Healthcare Act.
1 Working together for better Health in China Public & Private Partnership in Health Dr. Henk Bekedam WHO Representative China China Healthcare PPP Forum.
Trends In Health Care Industry KNH 413. Difficult questions What is health insurance? What is health care versus health insurance? Is one or both a right.
Healthcare Reform in China and Its Impact on the Pharmaceutical Industry Hengpeng Zhu Institute of Economics Chinese Academy of Social Sciences
Economic Evaluation of Health Technology: Overview Gerald F. Kominski, Ph.D. Professor, UCLA Department of Health Services.
Health financing models. NHS Systems Strengths –Pools risks for whole population –Relies on many different revenue sources –Single centralized governance.
Impact of Hospital Provider Payment Mechanism on Household Health Service Utilization in Vietnam (preliminary results) Sarah Bales Public Policy in Asia,
Lecture 14 Policy, Legal, and Regulatory Issues in HIS (Chapters 18,19,20)
OCCUPATIONAL SAFETY AND HEALTH IN GHANA Ghana has a mixed economy dominated by agriculture, commerce, service and industry.
Whilst the pharmaceutical industry plays a key role in developing and producing medicines, there is a tension between industry’s need to expand product.
by Joint Commission International (JCI)
New methods of financing the health system in Republic of Albania Elvana HANA General Director Health Insurance Institute Tirana on 09 June 2008.
The Czech Health System – its Presence and Future Pavel Hroboň L.Dittrich.
Public-Private Partnerships -Selected Experiences in the Western Pacific & Cambodia- National Forum on Public-Private Partnership in Health 7 November,
TBS Seminar on Essential Medicines and Health Products Geneva, 29 October 2013 Matthew Jowett, PhD Senior Health Financing Specialist Dept. Health Systems.
Cambodia1. 2 Cambodia Assessment Ung Phirun Chroeng Sokhan.
Summary from the Economics Track With thanks to all track participants, presenters, rapporteurs, moderators and organizers.
Svetlana Spassova, MD Ministry of Health, Bulgaria Chisinau
Pharmaceutical system strengthening – Is there a need for a new paradigm? Andreas Seiter The World Bank ICIUM 2011, Antalya 1.
CHALLENGING BOUNDARIES Rhodia way, The way we do business.
Paula Munderi Department of Essential Drugs and Medicines Policy World Health Organization Access to essential medicines for HIV/AIDS - update on WHO activities.
ACCESS TO MEDICINES - POLICY AND ISSUES
Policy track summary ICIUM 2011 – 18 Nov Policy track topics 1.The pharmaceutical policy process 2.Quality and safety of medicines in LMIC 3.Policy.
Issues in Health Sector Sanjib Pohit December 4, 2006.
CHAPTER V Health Information. Updates on new legislation (1)  Decision No.1605/2010/QĐ-TTg approving the National Program for Application of information.
WHO-Technical Briefing Seminar | October-November 2012 Dr Cécile Macé 1 |1 | Good Governance for Medicines Programme Dr Cécile Macé EMP/MPC.
Chapter 7.2 Examination and Treatment Prepared by Nguyen Trong Khoa.
1 SADC POOLED PROCUREMENT STRATEGY FOR ESSENTIAL MEDICINES & HEALTH COMMODITIES AARTI PATEL: TA SADC PBP BOTSWANA NATIONAL TRIPS & IP WORKSHOP.
MEDICAL SERVICE ADMINISTRATION VIETNAM MINISTRY OF HEALTH
HEALTH FINANCING MOH - HPG JAHR UPDATE ON POLICIES Eleventh Party Congress -Increase state investment while simultaneously mobilizing social mobilization.
Strengthening quality assurance system in hospital management Yuriy Azamatov Medical Accreditation Commission Bishkek
Portfolio Committee for Health Medicines and Related Substances Amendment Bill (06/08/08) IMSA represents Research Based Pharmaceutical Companies.
The Health of the Nation. Judging the Health of a Nation Quality of its doctors and medical institutions Doctors from all over the world come to the U.S.
Implementing health sector reforms and addressing public financing constraints: can they go hand in hand? Irina Smirnov, Economist, The World Bank.
The community pharmacy environment HMI Public Hearing Set 1 Hearing 2
Overview of China’s health care reform Wen Chen, Ph.D., Professor Fudan School of Public Health March 21, 2016.
1 CHALLENGES IN REGULATING QUALITY AND RATIONAL USE OF ANTIBIOTICS ALLIANCE FOR THE PRUDENT USE OF ANTIBIOTICS: INAGURAL MEETING COURTYARD.
The First Conference for Medicines Regulatory Authorities In Sudan and Neighboring Countries Khartoum December 2014 Alain PRAT, Technical Officer,
F8: Audit and Assurance. 2 Audit and Assurance Designed to give you knowledge and application of: Section A: Audit Framework and Regulation Section B:
Steps for the Integration of Traditional Medicine in the National Health Care Delivery System 18 TH ICASA Special Session on Traditional Medicine 1 st.
EHealth Development Vision. eHealth ojectives Healthcare systems and network focused on the patient: Not patient runs between institutions but the patients’
Organization and Implementation of a National Regulatory Program for the Control of Radiation Sources Program Performance Criteria.
Ministry of Labour, Health and Social Affairs of Georgia Development of e-Health system in Georgia.
Palestinian Health Sector Reform And Development Project “The Flagship Project” The Palestinian Health Conference “Toward Quality and Sustainable Health.
THE ROLE OF NON CUSTOMS AGENCIES IN A FULLY FLEDGED CUSTOMS UNION, EAC FORUM ON CUSTOMS UNION By Dr. Terry Kahuma, Executive Director, UNBS.
Benefits Design Covering all needed health services in designing health insurance benefits “Who Pays What? “Iran's new experience” “Iran's new experience”By.
An Economic Perspective
The Czech Health System – its Presence and Future
HEALTH INSURANCE PLANS
Convening today at TIFR, Mumbai on 29th January, 2017, on the occasion of the Tata Memorial Centre Platinum Jubilee Conference – ‘Healthcare – a commodity.
HEALTH INSURANCE PLANS
Effective Quality Assurance in Healthcare, Kyrgyzstan
National Pharmacy Practice Standards the Regulatory Role
Advancing Telemedicine Adoption in Europe – Developing capacities
Tobey Clark, Director*, Burlington USA
An Enabling Business Environment and A Strategic Collaborative Approach for Sustainable Quality Local Production Africa Pharma Conference 4-5 June 2019,
How can we make healthcare purchasing in Kenya more strategic?
Presentation transcript:

Towards a more effective healthcare regulation system in China China Health System Study Group Harvard School of Public Health Presented by Wensheng Fan, PHD At the APHA Meeting, Nov. 5, 2007

Outline Background Background Current situation Current situation Fundamental Challenges Fundamental Challenges Recommendations for healthcare regulation improvement in China Recommendations for healthcare regulation improvement in China

Framework of Health System Analysis Regulation Public health provision Medical care provision Resource GenerationFinancing & Payment HEALTH

Background: needs to regulate health care system in China

Two major pressing issues facing China ’ s healthcare system Cost escalation Cost escalation Medical quality & safety Medical quality & safety

Cost escalation

The majority portion of cost escalation is borne by the patients ’ OOP

Why cost escalation? Market-oriented reform of the health care system has changed the incentives of health facilities Market-oriented reform of the health care system has changed the incentives of health facilities Health facilities rely more on users ’ fee-for-service payments to raise revenue with much less government subsidies. Health facilities rely more on users ’ fee-for-service payments to raise revenue with much less government subsidies. Prescription drugs and diagnostic/treatment technologies are allowed a markup beyond cost which creates incentives for providers to provide more services or use more expensive services. Prescription drugs and diagnostic/treatment technologies are allowed a markup beyond cost which creates incentives for providers to provide more services or use more expensive services. The incentives & behaviors of providers are not well regulated by proper mechanisms The incentives & behaviors of providers are not well regulated by proper mechanisms

Cost escalation also leads to … Lower utilization rate of health care services Lower utilization rate of health care services Unequal access to basic health care services Unequal access to basic health care services Public dissatisfaction with the health care system Public dissatisfaction with the health care system

Medical quality & safety Conflicts between doctors and patients due to medical accidents & errors have increased significantly in recent years Conflicts between doctors and patients due to medical accidents & errors have increased significantly in recent years Counterfeit drugs & low quality drugs are still in the market; incidences of adverse drug reaction are happening with greater frequencies Counterfeit drugs & low quality drugs are still in the market; incidences of adverse drug reaction are happening with greater frequencies Inappropriate use of services lowered quality and safety (eg. Misuse of antibiotics) Inappropriate use of services lowered quality and safety (eg. Misuse of antibiotics)

Drug safety ---The New York Times, Oct 31, 2007

Regulation of the health care system in China needs to be strengthened to … Contain escalating cost (ensure cost-effectiveness) Contain escalating cost (ensure cost-effectiveness) Improve medical quality and safety (assure the legal rights and interests of both patients and medical practitioners) Improve medical quality and safety (assure the legal rights and interests of both patients and medical practitioners)

Current situation of health care regulation in China

Framework for health care regulation analysis Health facilities Drugs Healthcare Personnel Entry Quality Quantity Price Competitive Practices What to regulate? Which Variables to regulate? Who regulates?

Regulations related to cost containment What to regulate Variables Regulatory Entities Health facilities Price (payment ) SDRC, MOH,SACP,MOLSS Competitive Practices MOH, SAIC DrugsEntrySFDA PriceSDRC SDRC: State Development and Reform Committee MOH: Ministry of Health MOLSS: Ministry of Labor and Social Security SACP: State Administration for Commodity Prices SAIC: State Administration for Industry & Commerce SFDA: State Food and Drug Administration

Problems with the above regulations Price/payment regulations of health facilities: Price/payment regulations of health facilities: Central government sets price guidelines and provincial governments set the actual prices of medical services. But a flexible markup is allowed for new equipments & treatments. Since the providers decide which services to use, they choose to use more expensive treatments which causes the government ’ s price regulation to fail. Central government sets price guidelines and provincial governments set the actual prices of medical services. But a flexible markup is allowed for new equipments & treatments. Since the providers decide which services to use, they choose to use more expensive treatments which causes the government ’ s price regulation to fail. Government subsidy to hospitals is based on the scale of the hospital, not performance Government subsidy to hospitals is based on the scale of the hospital, not performance Payment from social insurance to hospitals is usually fee for service Payment from social insurance to hospitals is usually fee for service

Problems with the above regulations (cont.) Competitive practice regulations of health facilities: Competitive practice regulations of health facilities: Hospitals compete to attract more patients by getting high-tech equipment, while regulations on purchasing high-tech medical equipment by hospitals is weak. This increases the overuse of high-tech services. Hospitals compete to attract more patients by getting high-tech equipment, while regulations on purchasing high-tech medical equipment by hospitals is weak. This increases the overuse of high-tech services. Medical advertisements are regulated by different ministries and not well implemented Medical advertisements are regulated by different ministries and not well implemented

Problems with the above regulations (cont.) Entry regulation of drugs (drug registration) : the standards are too low for new drug registration and serious corruption at SFDA during the process of drug registration Entry regulation of drugs (drug registration) : the standards are too low for new drug registration and serious corruption at SFDA during the process of drug registration Price regulation of drugs Price regulation of drugs SDRC sets price guidelines for a large number of drugs, but new drugs are allowed to set prices above the guideline prices. So pharmaceutical companies choose to register their products as new drugs by making minor changes to take advantage of the price privilege SDRC sets price guidelines for a large number of drugs, but new drugs are allowed to set prices above the guideline prices. So pharmaceutical companies choose to register their products as new drugs by making minor changes to take advantage of the price privilege The policy of Centralized Drug Purchasing Through Bidding failed because of the corruption in the bidding process and bribes by drug companies to medical providers The policy of Centralized Drug Purchasing Through Bidding failed because of the corruption in the bidding process and bribes by drug companies to medical providers

Regulations related to medical quality & safety What to regulate Variables Regulation Entities Health facilities EntryMOH Quality MOH, NGOs, Juridical System Healthcare personnel Entry & Quality MOH, NGOs DrugsQuality SFDA, MOH

Problems with the above regulations Entry regulations on health facilities and healthcare personnel: Loose in suburban & rural areas, uncertified practitioners lead to potential medical risks Entry regulations on health facilities and healthcare personnel: Loose in suburban & rural areas, uncertified practitioners lead to potential medical risks Quality regulations of health facilities: Quality regulations of health facilities: Current practice guidelines have not become regulations but only provide guidance and not vigorously followed Current practice guidelines have not become regulations but only provide guidance and not vigorously followed Accreditation of hospitals is government-driven and become superficial Accreditation of hospitals is government-driven and become superficial Current regulations for medical conflict settlements are biased which impair the rights of both patients and medical practitioners in different circumstances Current regulations for medical conflict settlements are biased which impair the rights of both patients and medical practitioners in different circumstances

Problems with the above regulations (cont.) Quality regulations of drugs Quality regulations of drugs The quality of drug manufacture is inspected by local FDAs, who also take into consideration of the local economic contribution of the drug companies thus could not implement regulations vigorously The quality of drug manufacture is inspected by local FDAs, who also take into consideration of the local economic contribution of the drug companies thus could not implement regulations vigorously The quality issues in drug use are regulated by MOH. The fragmentation of responsibilities leads to coordination and accountability problems The quality issues in drug use are regulated by MOH. The fragmentation of responsibilities leads to coordination and accountability problems

Fundamental Challenges of health care regulation in China

Fragmented structure of the regulatory system Fragmented structure of the regulatory system Dependency of interests: the regulatory body (MOH) owns and manages the regulated (public hospitals) Dependency of interests: the regulatory body (MOH) owns and manages the regulated (public hospitals) Lack of accountability : corruption and dereliction of duty Lack of accountability : corruption and dereliction of duty Lack of capacity: non-professional human resources and outdated regulatory mechanisms Lack of capacity: non-professional human resources and outdated regulatory mechanisms Lack of social participation in the regulation system Lack of social participation in the regulation system

Recommendations for health care regulation improvement in China

Integrate fragmented regulatory functions across ministries with the ultimate goal of forming a “ National Health Committee ” Integrate fragmented regulatory functions across ministries with the ultimate goal of forming a “ National Health Committee ” Reform the governance structure of the public hospitals, making the government regulatory entities independent of the hospitals. Then the government could act on behalf of the public to regulate the providers Reform the governance structure of the public hospitals, making the government regulatory entities independent of the hospitals. Then the government could act on behalf of the public to regulate the providers

Increase accountability by strengthening intra- government regulations and making the regulatory entities accountable for regulation failures Increase accountability by strengthening intra- government regulations and making the regulatory entities accountable for regulation failures Improve regulation capacity by enhancing the professional capacity of the regulatory human resources and employing new regulatory methods such as information disclosure and performance assessment Improve regulation capacity by enhancing the professional capacity of the regulatory human resources and employing new regulatory methods such as information disclosure and performance assessment Involve more social participation in the regulation process, such as the media and professional NGOs Involve more social participation in the regulation process, such as the media and professional NGOs

Thank You